Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07274072

Hospital at Home Versus Inpatient Care: Costs and Effectiveness

Background and Objectives Hospital at Home (HaH) delivers hospital-level treatment to acutely ill patients in their own homes, including daily medical and nursing visits, infusions, physiotherapy, and diagnostics. It bridges inpatient and outpatient care, working closely with hospitals, office-based physicians, home care services (Spitex), and therapy providers.

There are two main pathways:

Admission Avoidance: stable patients requiring hospitalization are admitted directly to HaH instead of an inpatient ward.

Early Supported Discharge: patients treated in hospital are discharged earlier than usual and transferred to HaH.

Evidence International studies show HaH to be safe and effective. Reviews report comparable mortality and rehospitalization, shorter hospital stays, and cost advantages. Admission avoidance is linked to trends toward lower mortality and costs. Research showed similar mortality but fewer rehospitalizations, longer treatment duration, and reduced risks of institutionalization, depression, and anxiety. HaH patients were older, with reduced daily living activities, yet care costs were on average USD 5,054 lower than inpatient care.

In Switzerland, the mean hospital stay in 2019 was 8 days (acute somatic: 5.2; psychiatry: 33.5).

Study Hypotheses

HaH can be delivered at equal or lower cost than regular hospitalization.

HaH care is safe, with few complications, and yields high patient satisfaction.

Study Objective To demonstrate that hospital-equivalent home treatment of acutely ill patients is effective, appropriate, cost-efficient (according to Swiss WZW criteria), safe, and associated with high satisfaction and low complication rates compared with inpatient care.

Endpoints

Primary: Costs - HaH vs. inpatient care at Hirslanden Clinic, using REKOLE® cost accounting.

Secondary: Mortality, therapy type, monitoring, diagnostics, rehospitalization, complications, satisfaction, patient-reported outcomes, length of stay, referrals to nursing homes, follow-up after discharge, ED visits, rehabilitation referrals, and home care type.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Hospital at Home AG

Zollikon, Canton of Zurich, 8702, Switzerland

Location status: Recruiting

About this study

  • BACKGROUND AND SIGNIFICANCE OF THE STUDY

The Hospital at Home concept enables hospital-equivalent treatment of acutely ill patients requiring hospitalization in their own homes. Treatment is carried out as in a regular hospital, with daily visits by physicians and nurses. In addition to disease management, including infusion therapies, home-based physiotherapy and diagnostic procedures such as blood and urine testing, ultrasound, and electrocardiography are provided.

This positions Hospital at Home at the interface between traditional inpatient and outpatient care, complementing the existing services of hospitals, office-based physicians, home care organizations (Spitex), physiotherapy, and occupational therapy through a structured treatment process at the patient's home. Care is not provided in isolation but in cooperation with the aforementioned established institutions.

Two referral pathways into Hospital at Home can be distinguished:

Admission Avoidance: eligible patients in stable general condition with an acute illness that would normally require hospitalization are admitted directly into Hospital at Home instead of inpatient care and treated equivalently at home.

Early Supported Discharge: patients already treated in a regular hospital and in good general condition are discharged earlier than usual and transferred to Hospital at Home, where treatment is completed.

Hospital at Home has been investigated in various international studies. A review found, patients assigned to Hospital at Home via early supported discharge showed comparable mortality and rehospitalization rates and shorter hospital stays. Patients admitted via admission avoidance showed a trend towards lower mortality and costs and comparable rehospitalization rates.

Further research found similar mortality rates between Hospital at Home and regular inpatients, but lower rehospitalization rates and longer treatment durations in the Hospital at Home group. It also showed lower risk of institutionalization in long-term care facilities, as well as a reduced risk of depression and anxiety.

A retrospective observational study from New York, USA, showed, that Hospital at Home patients were on average older and showed reduced activities of daily living. The costs of Hospital at Home care were on average USD 5054 lower than those of comparable inpatients.

In Switzerland in 2019, the average length of stay across all hospital sectors was 8.0 days, with the shortest in acute somatic care (5.2 days) and the longest in psychiatry (33.5 days).

  • PROJECT OBJECTIVES AND DESIGN 2.1 Hypotheses and Primary Study Objective

Hypothesis 1 Care through Hospital at Home can be delivered at equivalent or lower cost compared to regular hospitalization.

Hypothesis 2 Hospital at Home care is safe for patients, associated with few complications, and yields high patient satisfaction.

Study Objective Our study aims to demonstrate that hospital-equivalent treatment of acutely ill patients at home is effective, appropriate, and cost-efficient (according to the Swiss WZW criteria) and, compared with regular inpatient care, is safe, associated with low complication rates, and achieves high patient satisfaction.

2.2 Primary and Secondary Endpoints

Primary Endpoint:

Costs: Treatment in Hospital at Home can be cost-equivalent or more cost-effective compared to regular inpatient care. Patient data from Hospital at Home AG will be compared with patient data from regular inpatients at Hirslanden Clinic. Costs, or billable tariffs, will be considered based on cost accounting according to REKOLE®.

Secondary Endpoints (as defined in section 3.3 "Additional Study Variables"):

Mortality

Type of therapy

Type of monitoring

Type and frequency of diagnostics

Rehospitalization during and after treatment

Complications and complication rates

Patient satisfaction

Patient-related outcomes

Length of stay

Referrals to nursing homes or long-term care after discharge

Follow-up with general practitioner or specialist after discharge

Emergency department visits during treatment and after discharge

Referral to rehabilitation clinics after discharge

Type of home care after discharge

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Inpatients in the hospital or patients in Hospital at Home care
  • Age ≥ 18 years
  • Admission due to a typical Hospital at Home diagnosis (mild to moderate inflammatory and infectious diseases of the lungs, urinary tract, gastrointestinal tract, heart, and skin; exacerbated chronic obstructive pulmonary disease; exacerbation of chronic heart failure; wounds; bleeding/anemia; dehydration; deterioration of general condition in multimorbid patients; infection-related complications in oncological patients; psychiatric problems including delirium; metabolic or autoimmune diseases; orthopedic patients; pain exacerbations of any cause; palliative patients up to and including terminal situations)
  • Patients without severe cognitive impairment or dysfunction who are capable of providing informed consent and/or completing the questionnaire
  • Patients with sufficient proficiency in written and spoken German and/or English

Exclusion criteria

  • Inpatient admission for other reasons
  • Refusal to provide informed consent

Treatment and study plan

Primary outcomes

  1. Costs

    Time frame: 1 year or until the total of 200 participants are included

    Comparison of cost of treatment in Hospital at Home vs. regular hospital ("brick and mortar"). Data will be collected via financal data of both groups, 100 patients from the regular hospital (Klinik Hirslanden Zurich) and 100 patients from Hospital at Home AG (Zollikon)

Secondary outcomes

  1. Effectiveness (clinical outcome)

    Time frame: 1 year or until the total of 200 participants are included

    Measure of how effective the treatment in Hospital at Home vs. regular hospital ("brick and mortar") is. The clinical outcome will be measured by: Mortality up to 30 days after discharge, emergency-admission up to 30 days after discharge, readmission to the hospital/H@H up to 30 days after discharge, GP-consultation up to 30 days after discharge, specialist-consultation up to 30 days after discharge, admission to nursing home up to 30 days after discharge. Data will be collected through patient data, collected via clinical information system and phone calls to the patient 30 days after discharge.

  2. Effectivness (complications)

    Time frame: 1 year or until the total of 200 participants are included

    Measure of how effective the treatment in Hospital at Home vs. regular hospital ("brick and mortar") is. The clinical outcome will be measured by measuring the number and kind of complication. We will collect data regarding number of falls, (up to 30 days after discharge), number of new infections during treatment, development of bedsores during treatment (yes/no), development of delirium during treatment (yes/no), thrombosis during treatment (yes/no). Data will be collected through patient data, collected via clinical information system and phone calls to the patient 30 days after discharge.

  3. Patient satisfaction

    Time frame: 1 year or until the total of 200 participants are included

    How satisfied are the patients treated in Hospital at Home compared to patients treated in the regular hospital ("brick and mortar"), measured by patient questionnaires. First questionnaire (patient satisfaction) consists of 8 questions each reaching from 0-5 points (0 = worst, 5 = best) regarding overall assessment, recommendation of service, assessment by relatives, competencies of nurses, competencies of doctors, quality of hotline, satisfaction with communication/flow of information and safety. Second questionnaire ist the PROMIS Globla health 10 consisting of 10 questions, first 9 reaching from 1-5, last question reaching from 0-10 points. The questions assess global well-being, quality of life, physical and psychological well-being, satisfaction with level of activity, handling of everyday activities, handling of everyday phsysical tasks, mental problems, tiredness, pain. Data will be collected through patient data, collected via clinical information system and phone calls.

Other outcomes

  1. patient data

    Time frame: 1 year or until the total of 200 participants are included

    Data regarding demographics including name, date of birth, age, sex, language, distance hospital to home, date of death, date of admission/discharge, length of stay, ICD-codes, -chapters, major diagnostic chapters, type of insurance, billing, referrer, living situation (alone yes/no), care situation (independent, nursing home), nr of drugs ad admission/30d post discharge, polypharmacy (defined as >5 drugs at admission), nr of chronic comorbidities, Charlson comorbidity score/-10 year survival rate, cognitive impairment (yes/no), i.v.-medication during treatment (yes/no, duration), monitoring (yes/no, duration), nr of hotline calls/ringing of nurse, nr of doctor/nurses visits, nr of ecg/sonography/xray/expert consultation, yes/no of physiotherapy/O2-substitution.

    Data will be collected through patient data, collected via clinical information system and phone calls to the patient 30 days after discharge.

  2. result of first blood sample

    Time frame: 1 year or until the total of 200 participants are included

    Collection of results of first blood sample, taken at admission to hospital/H@H. Collection of white blood cell count G/l, hemoglobin g/l, CRP mg/l, natrium mmol/l, potassium mmol/l, creatinine umol/l, GFR ml/min/1.73m2, ALT U/l. Data will be collected through patient data, collected via clinical information system and phone calls to the patient 30 days after discharge.

  3. first vital signs measured at admission

    Time frame: 1 year or until the total of 200 participants are included

    Collection of values of first vital sign measurement at admission. Collection of SpO2 in %, body temperature in °C, blood pressure in mmHg, respiratory rate in x/min. Data will be collected through patient data, collected via clinical information system and phone calls to the patient 30 days after discharge.

Study contacts

Contact information is provided by the study sponsor or research team.

Kilian Braendle, Dr. med.

CONTACT

[email protected]

+41444553304

Natascha Furrer, Coordinator

CONTACT

[email protected]

+41443553300

Sponsors and collaborators

Lead sponsor

Hospital at Home AG

Industry

Collaborators

  • Klinik Hirslanden, Zurich

Registry information

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Dec 10, 2025
Registry last updated
Dec 10, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.